Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.70 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.70 |
| ▸ | NPC1 | O15118 | 1/20 | 0.62 |
| ▸ | RAB9A | P51151 | 1/20 | 0.62 |
| ▸ | MGLL | Q99685 | 3/20 | 0.58 |
| ▸ | FAAH | O00519 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10459207 | 0.87 | CYP1A2 (0.69) | CYP1A2CYP2D6MGLL | |
| SCHEMBL26042174 | 0.85 | CYP1A2 (0.69) | CYP1A2CYP2D6MGLLFAAH | |
| SCHEMBL18424173 | 0.85 | CYP1A2 (0.73) | CYP1A2CYP2D6MGLLFAAH | |
| SCHEMBL4000173 | 0.85 | CYP1A2 (0.66) | CYP1A2CYP2D6MGLLFAAH | |
| SCHEMBL636977 | 0.85 | CYP1A2 (0.66) | CYP1A2CYP2D6MGLLFAAH | |
| SCHEMBL2106015 | 0.85 | CYP1A2 (0.66) | CYP1A2CYP2D6MGLLFAAH | |
| SCHEMBL14389738 | 0.84 | CYP1A2 (0.65) | CYP1A2CYP2D6MGLLFAAH | |
| SCHEMBL640619 | 0.84 | CYP1A2 (0.76) | CYP1A2CYP2D6NPC1RAB9AMGLL | |
| SCHEMBL8483965 | 0.83 | MAPT (0.65) | CYP1A2CYP2D6MGLL | |
| SCHEMBL4018355 | 0.83 | CYP1A2 (1.00) | CYP1A2CYP2D6MGLLFAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8163767-B2 | Heterocyclic Janus Kinase 3 inhibitors | ASTELLAS PHARMA INC. (JP) | 2012-04-24 | — | — | US | disclosed |
| EP-2251341-A1 | Heterocyclic Janus kinase 3 inhibitors | Astellas Pharma Inc. (JP) | 2010-11-17 | — | — | EP | disclosed |
| US-20090264399-A1 | HETEROCYCLIC JANUS KINASE 3 INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2009-10-22 | — | — | US | disclosed |
| EP-1910358-A2 | HETEROCYCLIC JANUS KINASE 3 INHIBITORS | Astellas Pharma Inc. (JP) | 2008-04-16 | — | — | EP | disclosed |
| WO-2007007919-A2 | HETEROCYCLIC JANUS KINASE 3 INHIBITORS | ASTELLAS PHARMA INC. (JP) | 2007-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264399-A1 | HETEROCYCLIC JANUS KINASE 3 INHIBITORS | JAK3, JAK2, JAK1 | CYP1A2 2009/4885CYP2D6 2330/4885NPC1 4165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.